Status:
TERMINATED
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Lead Sponsor:
Asan Medical Center
Conditions:
COVID-19
Eligibility:
All Genders
16-99 years
Phase:
PHASE2
Brief Summary
In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical st...
Detailed Description
This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of lopinavir/ritonavir, hydroxychloroquine, or control arm.
Eligibility Criteria
Inclusion
- confirmed mild COVID-19 (NEWS scoring system 0-4)
Exclusion
- unable to take oral medication
- pregnancy or breast feeding
- immunocompromised patients
- creatinine clearance (CCL) \< 30 mL/min
- aspartate transaminase (AST) or alanine transaminase (ALT) \> 5 times Upper limit of normal (ULN)
Key Trial Info
Start Date :
March 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04307693
Start Date
March 11 2020
End Date
April 30 2020
Last Update
May 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea, 138-736